Phase I/II study of two different schedules of bortezomib (Velcade, PS-341) and pemetrexed (Alimta) in advanced solid tumors, with emphasis on non-small cell lung cancer (NSCLC)

Trial Profile

Phase I/II study of two different schedules of bortezomib (Velcade, PS-341) and pemetrexed (Alimta) in advanced solid tumors, with emphasis on non-small cell lung cancer (NSCLC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Aug 2007 Status change from suspended to completed.
    • 24 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top